Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
This is used to treat central diabetes insipidus and bedwetting
Subscribe To Our Newsletter & Stay Updated
